



Address: Portcullis TrustNet (BVI) Limited
Portcullis TrustNet Chambers, P.O. Box 3444
Road Town, Tortola, British Virgin Islands
Phone: (284) 494 5296
Fax: (284) 494 5283
E-mail: a2hmall@a2hmall.com
Website: <http://www.a2hchina.com>

Date: 11, 0 APR 2016

National Stock Exchange of Australia Limited
Level 13
575 Bourke Street
Melbourne
Victoria 3000

Attn: Mr Ian Craig

Dear Sir,

RE: PROPOSED LISTING ON THE NATIONAL STOCK EXCHANGE OF AUSTRALIA LIMITED
- ANTI-AGING HOUSE HOLDING LIMITED (BVI: 1570095 and ARBN: 606 301 106) ("A2H" or the "Company")

The Company is proposing to apply for the listing of and quotation for all its CHESS Depository Interest (CDIs) on the National Stock Exchange of Australia Limited.

In furtherance there, we set out below the relevant requested information of our Company for your kind consideration:

1. General

- (1) the name of the applicant and the date and place of incorporation;

ANTI-AGING HOUSE HOLDING LIMITED (1570095) is a company incorporated and registered in British Virgin Islands, on 5 February 2010.

- (2) if not incorporated in Australia, the date on which the applicant became registered under the Corporations Act;

ANTI-AGING HOUSE HOLDING LIMITED was registered as a foreign company in Australia with ARBN: 606 301 106 on 1 July 2015.

- (3) the address of the principal registered office and the address of each office at which a share register is kept;

The registered office of the Company is located at Portcullis TrustNet Chambers, P.O. Box 3444, Road Town, Tortola, British Virgin Islands.

- (4) a formal request for the listing of the securities in respect of which application is made, specifying the nature of the securities and the amount, class, the voting rights attached and whether they are to be fully paid;**

We formally request for the listing of the Company's 93,251,251 CHESS Depository Interest ("CDIs").

Each CDI entitles its holders to one underlying Share. The 93,251,251 Shares in issue by the Company are Ordinary Shares having the rights as prescribed by the Articles of Association of the Company and are represented by the CDIs. The holders of CDIs in the Company are entitled to one vote per share in a General Meeting on any matter that can be voted upon by the Shareholders. The holders of Shares have no pre-emptive or other rights to subscribe for additional Shares. All issued Shares are fully paid.

- (5) the proposed method by which the securities are to be brought to listing and details of any proposed distribution of the securities;**

The Company is proposing a compliance listing. As at the date of this application, the Company has 69 shareholders.

No new capital was raised or available to the Company as a result of this listing. The listing of the CDIs may have favourable consequences for the Company's shareholders who may wish to trade their CDIs through a stock exchange. The Listing of the CDIs on the NSX may also provide access to an efficient facility for executing any future transactions in CDIs of the Company.

- (6) the estimated market capitalisation of the securities for which a listing is sought;**

<i>Total shares on issue</i>	<i>93,251,251 shares</i>
<i>Shares represented by CDIs</i>	<i>93,251,251 CDIs</i>
<i>Estimated market price per CDI</i>	<i>AUD 0.20</i>
<i>Estimated market capitalization</i>	<i>AUD 18,650,250.20</i>

- (7) an estimate of the net proceeds of any proposed issue and the intended use of the proceeds; and**

The Company is proposing and seeking for a compliance listing on the NSX. Therefore, no proceeds will be raised from the compliance listing.

- (8) the name of any other stock exchange on which any securities of the issuer are already listed and/or traded.**

The Company's securities are not listed on any other stock exchange.

2. Share capital and ownership

(1) A list in tabular form of:

(i) the designation or title of each class of share;

The Company has one class of shares being fully paid ordinary shares.

(ii) the number of shares issued;

The Company has 93,251,251 ordinary shares currently in issue and intends to have 48,549,336 CDIs in issue of which 47,197,776 are escrowed for 12 months and 1,351,560 are escrowed for 24 months.

(iii) the voting rights attached to each share;

All Shares have the same voting right. Each Share has one vote.

(iv) the amount of fully paid up shares;

93,251,251 Shares

(v) the shareholdings of the directors and officers of the issuer; and

Please make reference to Section 9 of the Information Memorandum.

(vi) so far as is known, or can be ascertained after reasonable enquiry, the names of all shareholders of the issuer who own five percent (5%) or more of the shares of the issuer and their respective shareholdings.

Name	Shares	%
<i>Chen Dongliang</i>	<i>35,664,720</i>	<i>38.25%</i>
<i>AG Arts Investment Limited</i>	<i>9,251,251</i>	<i>9.92%</i>
<i>Right Ocean Investment Limited</i>	<i>8,235,360</i>	<i>8.83%</i>
<i>Wealth Chance Investment Limited</i>	<i>7,997,280</i>	<i>8.58%</i>
<i>Ren Yi</i>	<i>5,040,000</i>	<i>5.41%</i>

(2) A list in tabular form of the names of all shareholders of the issuer including the dates that the shares were allotted to them, the consideration that they provided and the number of shares that are held.

*A list of shareholders is enclosed as **Appendix 1** if this letter of application.*

3. Securities

An outline of the principal terms of the securities the applicant wishes to list.

The Company is going to list all its CDIs amounting to 93,251,251 CDIs. Please refer to Section 2 of the Information Memorandum.

4. History and nature of business

A short introductory paragraph describing the general nature of the business and products of the applicant. A brief history of the issuer for the last five (5) years or, if later, from inception to the date of the application. A description of the business now conducted by the issuer and its child entities, including principal products manufactured, services performed or investments held, principal markets for products and raw materials, method of marketing, annual turnover for the preceding three (3) financial years and for the current financial year to the latest date available.

Please make reference to Sections 4, 5, 9, 10, 11 and 12 of the Information Memorandum.

5. Summary of earnings

A summary of earnings, on a consolidated basis if the applicant has subsidiaries, for the last three (3) financial years, showing sales, earnings before charges for depreciation, interest and tax (if any), the amount of each of those charges, net income before extraordinary items, extraordinary items, net income and earnings per share.

Please make reference to Section 12 of the Information Memorandum.

6. Tabulation of balance sheet

A tabulation of its balance sheet for each of the last three (3) financial years (on a consolidated basis if the issuer has subsidiaries) or from the date of incorporation, if shorter. The tabulation should include a calculation of the net asset value per security for each of the three (3) financial years.

Please make reference to Section 12 of the Information Memorandum.

7. Employees

A statement as to the total number of persons regularly employed and, if subject to seasonal fluctuations, the maximum and minimum numbers employed during the preceding twelve (12) months.

A2H has 5 directors who are the 3 executive and 2 non-executive directors of the Company. The Company's subsidiary Anti-Aging House Technology (Wuhan) Company Limited employs 20 fulltime employees (including its 3 executive directors).

8. Child entities

A tabular list of all child entities showing in respect of each such corporation:-

- (1) the name of the corporation;
- (2) a brief statement of the nature of its business and its relationship to the operations of the entire enterprise; and
- (3) share capital by classes, showing the amount issued and the amount owned by the holding entity.

Subsidiaries Name	Nature of Business	Share capital by classes, amount issued and owned by the holding entity.
<i>Anti-Aging House International Limited</i>	<i>A holding company which was incorporated to hold 100% of the operating company in conjunction with the listing exercise.</i>	<i>The Company is the holder of 100% of the issued and fully paid-up ordinary shares of Anti-Aging House Internaitonal Limited.</i>
<i>Anti-Aging House Technology (Wuhan) Company Limited</i>	<i>Is the operating business which carries on the anti-aging business of the Group.</i>	<i>The total fully paid-up capital of Anti-Aging House Technology (Wuhan) Company Limited is RMB10,000,000.</i> <i>Anti-Aging House International Limited is the holder of 100% of Anti-Aging House Technology (Wuhan) Company Limited.</i>

9. Dividend record

State the number of consecutive years in which dividends have been paid. State the amount of dividend (per share and in the aggregate) paid by the applicant (and its child entities) for each of the three (3) preceding years. Indicate whether dividends have been paid on a quarterly, semi-annual or annual basis. State the record date, payment date and the date of declaration with respect to each dividend paid during the past two (2) years.

Neither the Company nor any of its subsidiary companies has declared or paid any dividends since incorporation.

10. Properties

Describe briefly the general character of the properties of the applicant and its child entities, including:

- (1) location;
- (2) land area;
- (3) number of buildings;
- (4) aggregate floor area of buildings; and

- (5) whether properties are owned or leased, and if leased, state total rental paid for each of the three (3) preceding financial years and average term of years.

<i>Location</i>	<i>Land Area</i>	<i>No. of Buildings</i>	<i>Aggregate floor area of buildings</i>	<i>Whether Property owned or leased</i>	<i>Total rental paid for each 3 preceding financial years</i>	<i>Term</i>
<i>No.551, Shamao Street Yucai Road, Hannan District, Wuhan City, Hubei Province, China</i>		<i>1</i>	<i>728.06 sq m</i>	<i>Leased</i>	<i>RMB12,000 per month</i>	<i>5-year from April 2015 to April 2020 with option to renew</i>

11. Litigation

Particulars of any litigation or claims of material importance made against any member of the group in the last five (5) years or which is pending or threatened against any member of the group, or an appropriate negative statement.

Neither the Company nor any of its subsidiary companies is involved in any pending or threatened litigation or claims in the last 5 years from the date of this letter.

12. Management

- (1) the full name, residential address and description (being his or her qualifications or area of expertise or responsibility) of every director or proposed director and any person who performs an important administrative, management or supervisory function and particulars of the principal functions performed by each of them within the group if significant to the group;

Name	Principle Function	Address
<i>Chen Jiwu</i>	<i>Executive Director/Executive Chairman/CEO</i>	<i>Room 202, Unit 1, Building 209, Heshan Village, Wuhan, Hubei Province, China 430050</i>

<i>Zhang Kejian</i>	<i>Executive Director/Vice President</i>	<i>Room 121, No. 40-135, Tawan Street, Huanggu District, Shenyang, Liaoning Province, China 110000</i>
<i>Du Ming</i>	<i>Executive Director/Sales Director</i>	<i>Room 603, Unit 3, Building 8, Gutiansi Road, Wuhan Province, China 430000</i>
<i>Chang Yingming</i>	<i>Non-Executive Director</i>	<i>Room 1401, Unit 2, Building 3, Xiju Garden, Feng Tai district, Beijing, China 100161</i>
<i>Sae Chen Jacky</i>	<i>Non-Executive Director</i>	<i>#41 Russian Cofederation BLCD, Phnom Penh, Cambodia</i>
<i>Li Jun</i>	<i>CFO</i>	<i>Room 515, No.58 Dazhi Road, Jiang An, Wuhan Province, China 430014</i>
<i>Mo Zhaohui</i>	<i>Chief Operations Officer</i>	<i>Room 501, No.18 Cuiweihe Road, Han Yang District, Wuhan Province, China 430050</i>
<i>Zhang Yang</i>	<i>Head of Warehousing</i>	<i>No.8 Taishi Road, Sha Shi, Jing Zhou, Wuhan Province, China 434000</i>

(2) the nature of any family relationship between the persons mentioned in (1);

There is no family relationship between the persons mentioned in (1).

(3) a brief account of the business experience of each of these persons during the last five (5) years;

Please make reference to Section 11 of the Information Memorandum.

(4) indicate any other directorships held by each director or proposed director in any publicly listed or traded companies; and

None of the directors hold any directorships in any publicly listed or traded companies.

(5) state if any director or proposed director has, in any jurisdiction, been convicted in any criminal proceeding or has had a bankruptcy petition filed against him or her or any partnership in which he was a partner or any body corporate of which he was a director or has been sanctioned or otherwise disciplined by any self regulatory securities association of which he or she is or has been a member or any securities supervisory or regulatory body or any such event is pending.

None of the Directors has, in any jurisdiction, been convicted in any criminal proceedings or has had a bankruptcy petition filed against him or her or any partnership in which he was a partner or any body corporate of which he was a director or has been sanctioned or otherwise disciplined by any self regulated securities association of which he is or has been a member of any securities supervisory or regulatory body or any such event is pending.

13. Sponsors, bankers, etc.

- (1) the names and addresses of the issuer's sponsor, financial advisers, principal bankers, nominated adviser, share registrar/transfer agent and solicitors; and**

The Company will seek NSX to waive the requirement to appoint a sponsoring broker. For details of the other parties, please make reference to Section 7 of the Information Memorandum.

- (2) the name, address and professional qualifications of the issuer's auditors.**

Please make reference to Section 7 of the Information Memorandum.

14. Statement of non-compliance

A statement of any requirements of the Listing Rules which cannot be met by the applicant and detailed arguments to support any request for a waiver or modification of the normal requirements.

Other than Listing Rule 2.2 from which the Company is seeking waiver, the Company will meet each of the requirements of the NSX Listing Rules.

15. Declaration

A declaration, stated to be to the best of the issuer's knowledge, information and belief that:

- (1) save as specified in the application letter, all the qualifications for listing set out in Chapter 3 of Section IIA of the Listing Rules have, in so far as applicable and required to be met and fulfilled prior to application, been met or fulfilled in relation to the issuer and the securities of the issuer the subject of the application;**
- (2) all information required to be included in the disclosure document pursuant to Rule 4.8 and the Corporations Act will be included; and**
- (3) there are no other facts bearing on the issuer's application for listing which, in the issuer's opinion, should be disclosed to the Exchange.**

EXECUTED BY ANTI-AGING HOUSE HOLDING LIMITED

by:

.....

Name: Chen Jiwu
Designation: Director



.....

Name: Du Ming
Designation: Director